



BETA DRUGS LTD

CORPORATE PRESENTATION



Disclaimer

- This corporate presentation has been prepared by Beta Drugs Limited (the “Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person.
- This presentation should not be construed as legal, tax, investment or other advice. This presentation is confidential, being given solely for your information and for your use, and may not be copied, distributed or disseminated, directly or indirectly, in any manner. Furthermore, no person is authorized to give any information or make any representation which is not contained in, or is inconsistent with, this presentation. Any such extraneous or inconsistent information or representation, if given or made, should not be relied upon as having been authorized by or on behalf of the Company.
- The information contained in this presentation is only current as of its date and has not been independently verified/ authenticated and are based upon to the best of the knowledge, belief and information. The Company may alter, modify or otherwise change in any manner the contents of this presentation, without obligation to notify any person of such revision or changes.
- No representation, warranty, guarantee or undertaking, express or implied, is or will be made as to, and no reliance should be placed on, the accuracy, completeness, correctness or fairness of the information, estimates, projections and opinions contained in this presentation. None of the Company or any of its affiliates, advisers or representatives accept any liability of whatsoever nature for any loss howsoever arising from any information presented or contained in this presentation. Please note that the past performance of the Company is not, and should not be construed as, indicative of future results.
- This presentation does not constitute or form part of and should not be construed as, directly or indirectly, any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of Beta Drugs Limited by any person in any jurisdiction, including in India or elsewhere, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any investment decision or any contract or commitment therefore.. This presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended, or any other applicable law in India. We undertake no obligation arising out of this information or any consequence arising therefrom.

Our Genesis



The Journey of Beta Drugs Limited (Adley Group) began early 80's with the ardent efforts of **Late Shri Vijay Batra**.

He was a visionary and businessman par excellence. He had foreseen the scope in niche segment like Oncology and laid the foundation of Indian Pharma Multinational in Oncology segment

From the beginning, he realized that if medicine had to serve their purpose, they first has to affordable and accessible

As guided by him, company is focusing on new product development that includes NIBs, NDDS & PARP inhibitors

Our Milestones



BETA DRUGS LIMITED

- 1983 Laid the foundation of Adley group by Late Shri Vijay Batra
- 2007 Entered into the Oncology market
- 2008 Set up 1st Oncology unit in Adley formulations Pvt Ltd.
- 2011 Foray into the international market
- 2014 Set up a new “state of art” manufacturing facility for Oncology formulations- Beta Drugs Limited
- 2015 Developed In-house Albumin bound Paclitaxel
- 2017 Received SME Excellence Award
Listed in NSE- National Stock Exchange
Commenced In-house API plant- Adley Labs
- 2018 Set up Oncology Plant in UZbekistan
Setup In-house PFS facility
- 2020 Launched GEM-RTU, ADLEAP (Enzalutamide)
Launched 1st Indian Brand of Dasatinib **BEEDAN**
- 2021 Launched 1st Indian Brand of Sunitinib **ADSUNIB**

Who we are



You build Hope...

We accelerate it

Because

*Every moment of life is precious for
cancer patients*

Our Mission

To touch the lives of million of cancer patients by expanding access of quality & affordable drugs through cutting edge technology & advanced R&D

Our Vision

To achieve a sustainable leadership in complex chemical synthesis for anticancer bulk drugs and finished dosages

Our Values

Care

Focus & accountability

Continuous improvement to create value

Cost effectiveness

Patient first approach

Collaboration & Partnership



Our Strength

Formulations and API Plant

BETA UBK INTERNATIONAL UZBEKISTAN

In October 2018, Beta Drugs entered into a joint venture with SILUJIN Private Co. Ltd, to manufacture Oncology drugs in Uzbekistan. Beta Drugs is first Indian company to manufacture Oncology drugs in the whole of Uzbekistan.

“State of Art” manufacturing facility has fully computerized HAVAC system, modern QA, QC, microbiological & PD Lab, sophisticated ETP plant & world class EHS system.

- Land:** 140000 Sq. Feet
- Formulations:** Cytotoxic Formulations (Orals Tablets & Capsules)
- Capacity:** 14 Million Tablets P.A
12Million Capsules P.A



API Plant

BETA DRUGS LIMITED INDIA

Beta Drugs Limited is a state-of-the-art manufacturing facility situated in Nandpur, Lodhimajra Road Solan, Himachal Pradesh, India.

It has WHO-GMP, and other international accreditations. The Unit is also geared for PICS inspections.

The plant has been audited and approved by almost all the recognized pharmaceutical companies of India to manufacture of their products for marketing in the local and overseas markets.

- Capacity:** 3.8 Million Liquid Injectables
- 1.4 Million Lyophilized Injectables
- 20 Million Tablets
- 18 Million Capsules



ADLEY FORMULATIONS PVT LTD INDIA

Adley formulation pvt Ltd is located in Kotla, Barotiwala, Distt. Solan Himachal Pradesh India.

It is WHO-GMP-approved Facility, dedicated to manufacturing of anti-cancer products (Tablets, Capsules, Injections- Liquid, Lyophilized and Pre-Filled Syringes). This plant also has international accreditations.

- Capacity:** 1.8 Million Liquid Injectables
- 0.8 Million Lyophilized Injectables
- 5 Million Tablets
- 4 Million Capsules
- 15000 PFS filling per day



ADLEY LAB. LTD INDIA



Our API manufacturing facility located in Derabassi, Punjab India.

It meets the cGMP standards and comply with all statutes of Pollution control, Environment, Health and Safety parameters. It is equipped with latest equipments at Lab scale, Kilo scale, pilot scale & commercial scale.

Our facility has technically and professionally competent to handle all the associated and inherent hazards and risks while manufacturing Oncological range of APIs. As a mandatory safeguard and to ensure maximum protection to staff handling oncology products, utmost care is taken to avoid cross-contamination and possible exposure to lead hazards.

- Capacity:** Line 1: 20 Tonnes P.A
Line 2: 40 Tonnes P.A.



beta drugs limited

Our Market Reach

DOMESTIC MARKET

Beta drugs Limited has leadership position in Indian market with 88 SKUs. Products are available in major corporate & Govt hospitals

Corporate Hospitals

Government Institutes

Our Product Portfolio



www.b-drugs.com

Solid Tumor

ADSUNIB Sunitinib Capsules 12.5/25/50mg	ADLEAP Enzalutamide Capsules 40mg	BEXINIB Axitinib Tablets 1/5mg	CAPAD Capecitabine Tablets 500mg	ADOXI Docetaxel Inj 20/80/120mg	ADPLATIN Oxaliplatin Injection 50/100mg
Adlante Lenvatinib Capsules 4/10 Mg	Gem-RTU Gemcitabine Inj 200mg/1g/1.4g (Ready to Use)	AMGICIN Gemcitabine Inj 200/1000mg	ADGEF Gefitinib Tablets 250mg	ERLOTAD Erlotinib Tablets 100/150mg	TEMOZAD Temozolomide Capsules 20/100/250 mg
HER-TINIB Lapatinib Tablets 250 mg	ADTRINIB Sorafenib Tablets 200 mg	RTU-DOCE Docetaxel Inj (Ready to Use)	ADPEM Pemetrexed Inj 100/500 mg	ADCARB Carboplatin Inj 150/450mg	ADCIST Cisplatin Inj 10/50mg
AB-PACLI Paclitaxel Protein-Bound 100 mg	ADPAXIL Paclitaxel Inj 30/100/260/300mg	FISTENT Fulvestrant Inj (250 mg /5 ml)	LETRAFEM Letrozole Tablet 2.5mg	ADNAST Anastrozole Tablet 1mg	ADRICIN Epirubicin Inj 10/50mg
ADMIDE Bicalutamide Tablets 50mg	ARBAZ Cabazitaxel Inj 60mg	ADBIRON Abiraterone Tablets 250mg	ADSIDE Etoposide 50mg Cap/ 100mg Inj.	ADVIN Vinorelbine Inj 50 mg	INOTAD Irinotecan Inj 100mg/5ml

Hematological Care

BEEDAN Dasatinib Tablets 20/50/70/100mg	ADMINE Imatinib Tablets 100/400 mg	MDS PLUS Azacitidine Inj 100mg	ADTRIB Doxorubicin Inj 10/50mg	ADRICIN Epirubicin Inj 10/50mg	ADSIDE Etoposide 50mg Cap/ 100mg Inj.
PEG-LASGEN Peg L-asparaginase Inj 3750 IU	L-ASGEN L-Asparaginase Injection 5000/10000 IU	ADSTEM Plerixafor Inj 24 mg	ADVIN Vinorelbine Inj 50 mg	ADFLU Fludarabine Inj 50ml	BUSFAN Busulfan Inj 60mg
BORTIAD Bortezomib Inj 2mg	ADLINOD Lenalidomide 5/10/25mg.	ADBEN Bendamustine Inj 100mg	ADCYCLO Cyclophosphamide Tablets 50mg	ADTHAL Thalidomide Capsule 50/100mg	ADXATE Methotrexate 2.5mg Tablets

Supportive Care


ADFILL Pegfilgrastim Inj 6mg	EMETANT-IV Fosaprepitant Inj 150mg	EMETANT Aprepitant Capsules 125/80mg	ADCUMIN ROYALE ORA-RINZ	ADDCURE Advanced Treatment Formula For Radiation Dermatitis
ADGRAM Granisetron Hydrochloride Inj	ALZIC Zoledronic Inj 4mg	Triodelta Tocotrienol Softgel Capsule 400 mg	Adcumin BIO-AVAILABLE NANOCURCUMIN	CAXFILA Megestrol Acetate Tablets IP

Domestic Market



Finished Formulation Sales

Domestic Formulation Sales (Cr)



Leading position in Oncology

- 2 Brands occupy No 1 position in India
- 6 Novel Molecules launched in FY 20-21
- 6 New Molecules to be launched in FY 21-22
- 1st One to launch Protein Shot

Exclusively dedicated to Oncology

Domestic Market

Current Position in Own Brand Sales


Oncology division overview

- Currently operating with 56 Molecules & 88 SKUs
- Sales and Marketing of product is supported by 36 Sales representatives and strategically located logistics network of over 125 distributors in India
- Currently available in around 70% of Corporate and Private hospitals
- Strong base of more than 600 Doctors


Solid Tumor



Hematology




Supportive Care



Number Of Active Brands

1st To Launch Molecules in India



Our Global Reach



BDL is ready to file PICS by June this year in its Formulations Plant.

BDL is also planning to file 1st DMF by October 2022 through its API Plant (Adley Lab Ltd.)

We are now globally represented by our subsidiaries or sales partners in over 15 Countries: Uzbekistan, Nigeria, Kenya, Uganda, Sri Lanka, Nepal, Myanmar, Yemen, Honduras, Venezuela, Tanzania, Ethiopia, Philippines, Malaysia & Ivory coast.

More than 50 products have been registered in these countries

With our research, development and marketing co-operations, we are determined to continue consolidating our position in the global pharmaceutical market. Our innovative, internationally oriented marketing strategy forms a sound basis for these efforts.

Beta Drugs in Oct, 2018 entered into a joint venture with SILUJIN Private Co. Ltd, to manufacture Oncology drugs in Uzbekistan. Beta Drugs is first Indian company to manufacture Oncology drugs in Uzbekistan.

Our Expertise-Regulatory



Our regulatory department works on the guidelines of CTD and ICH. Our team is engaged in day to day development of dossiers - DMFs, interacting with all the manufacturing sites to keep updating them for regular regulatory developments and features in the international arena. Teams also upgrade day to day operations of the plant, making sure that everything works in sync with the regulatory requirements.

Our Regulatory is constantly and continuously engaged in product registrations in various markets (domestic, emerging and regulated) across continents.

Our Accreditations





www.b-drugs.com


Our Strength- Strong In-house API development

VERTICAL INTEGRATION

API STRENGTH

- Complex Multi-Step Synthesis & Scale Up
- Containment & High Potency APIs
- Scale up of production Capacity

% Changes in vertical procurement by
Its subsidiary formulations



COMPANY'S FOCUS AND DETAILS:

- To launch APIs in the cytotoxic segment
- To be the first few players in the entry of new TKI's
- Enhancing the portfolio in Hematology segment
- Already launched 5 new APIs in 2020-21 and working to launch 3-4 products every year
- Company is aggressively working to file its first DMF (Europe) by October 2022

Plan To Expand Significant Augmented API Manufacturing Capacity



B-drugs PHARMACEUTICALS LTD.

Our Strength- Strong In-house API development

PRODUCT LIST (API)

Solid Tumor

DOCETAXEL TRIHYDRATE
ERLOTINIB HYDROCHLORIDE
GEFITINIB
LAPATANIB DITOSYLATE
PEMETREXED DISODIUM HEPTAHYDRATE
SORAFENIB TOSYLATE
TEMOZOLOMIDE
ENZALUTAMIDE
AXITINIB
SUNITINIB
LENVATINIB
METHOTREXATE

Hematology

AZACITIDINE
HYDROXYUREA
IMATINIB MESYLATE
LENALIDOMIDE
BORTEZOMIB
DASATINIB
BENDAMUSTINE HYDROCHLORIDE
PLERIXAFOR
IBRUTINIB

Supportive

APREPITANT
HYDROXYCARBAMIDE
ZOLEDRONIC ACID
FOSAPREPITANT

API UNDERDEVELOPMENT

ETOPOSIDE, BICALUTAMIDE, IRINOTECAN,
FULVESTRANT, ANASTROZOLE, NINTEDANIB
ABIRATERONE, BOSUTINIB, PAZOPANIB



Our Strength: Strong Research & Development (R&D)


Strong R&D capabilities demonstrated by its complex oncology formulations & oncology APIs

Beta Drugs limited is amongst a handful of Indian Oncology companies to foresee the importance of R&D and invest heavily in these activities.


We have highly accomplished team of dedicated scientists for process and analytical work, Pre-formulation studies, Physico-Chemical Characterization and Reverse Engineering

The R&D has ability to support small molecules, non-biological complex drugs. It has a wide range of chromatographic separation techniques and detection techniques to meet the requirement of different types of compounds.

It is in active collaboration for DCGI approved institutes for active bio-analytical studies to support preclinical and clinical studies during development phases.



R&D Expense (Lacs)



Our Indian Partners





BIO-DRUG LABORATORIES LTD.

BDL is acknowledged as a high quality manufacturing company by many leading pharmaceutical companies in India.

BDL has impressive clientele base of more than 49 Indian companies.



TRACK RECORD OF CONSISTENT GROWTH AND VALUE CREATION




Financial Performance




B. LA. DRUGS LTD.

Key Ratios


ROCE



ROE




CURRENT RATIO






Profitability Ratios


GROSS MARGIN



EBITDA MARGIN




OPERATING/EBIT






Solvency Ratios


DEBT RATIO



INTEREST COVERAGE RATIO



DEBT TO EQUITY RATIO





BETA DRUGS LTD.

Innovative product development is a result of our sustained efforts.

Contacts

Email: sales@betadrugslimited.com

Email: info@betadrugslimited.com

